MedTrace Logo

A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.

NCT01551797 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2012-12-10

No results posted yet for this study

Summary

This proof of principle study will evaluate an experimental formulation of paracetamol that is being developed for eventual long lasting use. This study is also used for drug safety evaluation.

Conditions

Interventions

DRUG

Paracetamol 500 mg

Standard Paracetamol formulation

DRUG

Paracetamol 1000 mg

Paracetamol Sustained Release formulation

DRUG

Paracetamol 750 mg

Paracetamol Sustained Release formulation

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01551797 on ClinicalTrials.gov